Clinical Trials · NCT00582426
Evaluation of Octreotide LAR in Prevention of Chemotherapy-induced Diarrhea
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Novartis Pharmaceuticals
- Enrollment
- 139
- Start date
- Apr 2008
- Locations
- 11 sites, Brazil
- Primary endpoint
- Percentage of Participants Developing Diarrhea (Grade 1 to 4)